TRIM55: A Potential Drug Target for Cancer and Tissue Homeostasis

Target Name: TRIM55

NCBI ID: G84675

TRIM55

TRIM55: A Potential Drug Target for Cancer and Tissue Homeostasis

TRIM55 (muRF2) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the murine retentionin (TR) family, which includes proteins that are involved in regulating protein levels in the body.

One of the unique features of TRIM55 is its ability to interact with the protein known as retinoblastoma gene (Rb) in a way that can inhibit its activity. This interaction between TRIM55 and Rb has important implications for the development and progression of certain diseases, including cancer.

In addition to its interaction with Rb, TRIM55 has also been shown to play a role in the regulation of cellular processes that are important for maintaining tissue homeostasis. This includes the regulation of cell division, cell migration, and the formation of tissues such as the nervous system and blood vessels.

TRIM55 is also of interest as a potential drug target because of its ability to interact with several different proteins, including Rb, TORC, and FAK. This makes it an attractive target for researchers to study and potentially develop as a new drug.

One of the challenges in studying TRIM55 as a drug target is its complex structure. The protein is composed of several domains, including an N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal TIR domain. These domains give TRIM55 its unique structure and function.

In addition to its unique structure, another challenge in studying TRIM55 is its expression. While TRIM55 is expressed in many different tissues throughout the body, its levels are often low. This makes it difficult to study its effects and determine if it is a suitable drug target.

Despite these challenges, researchers are making progress in understanding the role of TRIM55 in various biological processes. One of the most promising areas of research is the study of TRIM55's role in cancer progression.

Studies have shown that high levels of TRIM55 are associated with the development and progression of several types of cancer, including breast, ovarian, and prostate cancer. Additionally, TRIM55 has been shown to play a role in the regulation of cell division and the formation of cancer cells, which suggests that it may be a useful target for cancer therapies.

Another promising area of research is the study of TRIM55's role in the regulation of tissue homeostasis. These studies have shown that TRIM55 plays a role in the regulation of cell migration and the formation of tissues, which is important for maintaining tissue homeostasis.

TRIM55 is also of interest as a potential drug target because of its ability to interact with several different proteins, including Rb, TORC, and FAK. This makes it an attractive target for researchers to study and potentially develop as a new drug.

In conclusion, TRIM55 is a protein that is expressed in various tissues throughout the body that is of interest as a potential drug target due to its ability to interact with several different proteins, including Rb, TORC, and FAK. Further research is needed to fully understand its role in various biological processes and its potential as a drug target.

Protein Name: Tripartite Motif Containing 55

Functions: May regulate gene expression and protein turnover in muscle cells

The "TRIM55 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM55 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets